For example, inhibiting lipogenesis via suppressing the expression of ACCs can reduce hepatic steatosis, but it simultaneously results in hypertriglyceridemia due to the activation of SREBP-1c and increased VLDL secretion (40). The gene discussed is ACCS; the disease is Hepatic steatosis.